Limitations of Bispecific Agent Make Oral Option a Priority in Uveal Melanoma

David Savage, MD, PhD, of the University of New Mexico Comprehensive Cancer Center, outlines the distinct clinical hurdles in managing uveal melanoma, emphasizing the emotional, logistical, and therapeutic challenges patients face across disease stages. For localized disease, primary interventions, such as plaque radiotherapy or enucleation, often carry the significant cost of vision loss. For patients who develop metastatic disease, therapeutic options have historically been severely limited, as traditional systemic chemotherapies and immune checkpoint inhibitors demonstrate minimal efficacy.

An approved bispecific T-cell receptor, tebentafusp-tebn (Kimmtrak), has continued to improve survival in uveal melanoma, but its clinical utility is constrained by 2 main factors. The bispecific agent is only indicated for patients with HLA-A*02:01–positive expression, which excludes many patients with uveal melanoma for receiving this highly effective treatment. Secondly, there is a logistical burden astebentafusprequires weekly in-clinic infusions with mandatory step-up dosing if doses are missed. For rural populations traveling several hours to cancer centers, such as Savage’s patients in New Mexico, this regimen creates significant care disruption, he says.

Promising data presented at ASCO highlighted darovasertib (IDE196) plus crizotinib (Xalkori), an emerging, non-HLA-restricted oral targeted therapy that could significantly broaden access. Because its mechanism does not depend on a patient's inherited HLA type, it offers a universal therapeutic option across the broader metastatic population, and it demonstrated a 58% reduction in risk of progression or death vs physician’s choice in the HLA-A*02:01-negative patient population. Furthermore, as an oral regimen, it enables remote symptom management, relieving patients from demanding weekly travel schedules.

Although the oral targeted agent presents notable toxicities, primarily fatigue and gastrointestinal adverse events, Savage highlights that multidisciplinary teams can successfully manage these through proactive monitoring, dose delays, interruptions, or reductions. Anticipating potential regulatory approval in the coming years, clinicians view this emerging therapy as a vital opportunity to expand equitable treatment options and improve quality of life for patients facing metastatic uveal melanoma.